Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial
Bert H. O’Neil(Indiana University Health), Richard M. Goldberg(Ontario Institute for Cancer Research), Howard S. Höchster(Rutgers, The State University of New Jersey), Monica M. Bertagnolli(National Institutes of Health), Scott Berry(Queen's University), Jeffrey A. Meyerhardt(CancerCare), Claire Greene, Al B. Benson(Northwestern University), Richard L. Schilsky(American Society of Clinical Oncology), Briant Fruth(Mayo Clinic), Charles D. Blanke(SWOG Cancer Research Network), Alan P. Venook(University of California, San Francisco), Heinz‐Josef Lenz(USC Norris Comprehensive Cancer Center), Federico Innocenti(AbbVie (United States)), Peter Watson(McGill University), Robert J. Mayer(Applied Natural Sciences), Blasé N. Polite(Sidney Kimmel Cancer Center), Donna Niedzwiecki(Duke University), Eileen M. O’Reilly(Memorial Sloan Kettering Cancer Center), Daniel Mulkerin(University of Wisconsin–Madison), Deborah Schrag(Dana-Farber Brigham Cancer Center), James N. Atkins(Southeastern Medical Oncology Center), Anthony B. El-Khoueiry(USC Norris Comprehensive Cancer Center)
Cited by 96
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
How To Build and Interpret a Nomogram for Cancer Prognosis
|Journal of Clinical Oncology|2008|3.4k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k